Immatics extends cash runway into Q4 2028 as Q3 net loss widens to $86 million
Immatics · · AI-summarised by FinFlash
Cell therapy developer Immatics reported cash and financial assets of $536.3 million at the end of September and now expects its runway to last into the fourth quarter of 2028. Third-quarter collaboration revenue rose to $7.8 million from $5.9 million, while R&D spending climbed to $79.8 million and the net loss widened to $86.3 million. Topline data from its SUPRAME Phase 3 trial of anzu-cel are expected in the first half of 2027.
So What?
Longer runway reduces near-term dilution risk for IMTX; the 2027 Phase 3 readout is the key catalyst for the stock and TCR-T therapy peers.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.